Moreover, we find that expression of PTENP1-AS predicts clinical outcome in stage III melanoma patients, where high expression of PTENP1-AS in first regional lymph node metastases correlates with poor overall survival. Here, PTENP1 is linked to metastatic malignant neoplasm in the lymph nodes.